Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro

BACKGROUND: Gleevec (aka STI571, Imatinib) is a recently FDA approved anti-tumor drug for chronic myelogenous leukemia. Gleevec binds specifically to BCR-ABL tyrosine kinase and inhibit the tyrosine kinase activity. It cross-reacts with another two important membrane tyrosine kinase receptors, c-kit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peilin, Gao, Wei Yi, Turner, Steven, Ducatman, Barbara S
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2003
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149413/
https://www.ncbi.nlm.nih.gov/pubmed/12537587
http://dx.doi.org/10.1186/1476-4598-2-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149413/
https://www.ncbi.nlm.nih.gov/pubmed/12537587
http://dx.doi.org/10.1186/1476-4598-2-1

Ejemplares similares